Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck

References

• Ganci F, Sacconi A, Bossel BM, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, et al. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol. 2013;24:3082-8. https://doi.org/10.1093/annonc/mdt380. PMID:24107801
   PubMed Web of Science ®Google Scholar
• Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem. 2012;113:433-9. https://doi.org/10.1002/jcb.23400. PMID:22006292
   PubMed Web of Science ®Google Scholar
• Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F, Wu E. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48:2328-38. https://doi.org/10.1016/j.ejca.2012.03.001. PMID:22459764
   PubMed Web of Science ®Google Scholar
• Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:290-300. https://doi.org/10.1158/1078-0432.CCR-11-2260
   PubMed Web of Science ®Google Scholar
• Walerych D, Napoli M, Collavin L, Sal GD. The rebel angel: Mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012;33:2007-17. https://doi.org/10.1093/carcin/bgs232. PMID:22822097
   PubMed Web of Science ®Google Scholar
• Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie T-X, Zhang J, Wang J, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154-7. https://doi.org/10.1126/science.1206923. PMID:21798897
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576-82. https://doi.org/10.1038/nature14129. PMID:25631445
   PubMed Web of Science ®Google Scholar
• Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013;3:770-81. https://doi.org/10.1158/2159-8290.CD-12-0537. PMID:23619168
   PubMed Web of Science ®Google Scholar
• Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157-60. https://doi.org/10.1126/science.1208130. PMID:21798893
   PubMed Web of Science ®Google Scholar
• Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol. 2006;209:13-20. https://doi.org/10.1002/jcp.20689. PMID:16741928
   PubMed Web of Science ®Google Scholar
• Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J Cell Sci. 2003;116:4077-85. https://doi.org/10.1242/jcs.00739. PMID:12972501
   PubMed Web of Science ®Google Scholar
• Brosh R, Rotter V. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 2009;9:701-13. PMID:19693097.
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Prives C. Mutant p53: One name, many proteins. Genes Dev. 2012;26:1268-286. https://doi.org/10.1101/gad.190678.112 PMID:22713868.
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 2014;25:304-17. https://doi.org/10.1016/j.ccr.2014.01.021 PMID:24651012.
   PubMed Web of Science ®Google Scholar
• Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-29. https://doi.org/10.1002/humu.20495 PMID:17311302.
   PubMed Web of Science ®Google Scholar
• Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34(2):155–63. advance online publication. Available from: http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.3391.htmlhttps://doi.org/10.1038/nbt.3391
   PubMed Web of Science ®Google Scholar
• Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: Application to cancer genomics. Nucleic Acids Res. 2011;39(17):e118.https://doi.org/10.1093/nar/gkr407. PMID:21727090
   PubMed Web of Science ®Google Scholar
• Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552-61. https://doi.org/10.1056/NEJMoa073770. PMID:18094376
   PubMed Web of Science ®Google Scholar
• Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet. 2015;134:497-507. https://doi.org/10.1007/s00439-014-1470-0. PMID:25108461
   PubMed Web of Science ®Google Scholar
• Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014;46:939-43. https://doi.org/10.1038/ng.3051. PMID:25086664
   PubMed Web of Science ®Google Scholar
• Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression–potential mechanism for gain of function of mutant p53. Nucleic Acids Res. 2007;35:2093-104. https://doi.org/10.1093/nar/gkm099. PMID:17344317
   PubMed Web of Science ®Google Scholar
• Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004;23:5759-69. https://doi.org/10.1038/sj.onc.1207706. PMID:15208672
   PubMed Web of Science ®Google Scholar
• Han H, Shim H, Shin D, Shim JE, Ko Y, Shin J, Kim H, Cho A, Kim E, Lee T, et al. TRRUST: A reference database of human transcriptional regulatory interactions. Sci Rep. 2015;12(5):11432. Available from: http://www.nature.com/srep/2015/150612/srep11432/full/srep11432.html?WT.ec_id = SREP-20150616
   Web of Science ®Google Scholar
• Garritano S, Inga A, Gemignani F, Landi S. More targets, more pathways and more clues for mutant p53. Oncogenesis. 2013;2:e54.https://doi.org/10.1038/oncsis.2013.15. PMID:23817466
   PubMed Web of Science ®Google Scholar
• Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R, Resnick MA. Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res. 2013;41(15):7286-301. https://doi.org/10.1093/nar/gkt504. PMID:23775793
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9:402-12. https://doi.org/10.1038/nrm2395. PMID:18431400
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71:6051-60. https://doi.org/10.1158/0008-5472.CAN-11-1340 PMID:21791641
   PubMed Web of Science ®Google Scholar
• Tamura K. Development of cell-cycle checkpoint therapy for solid tumors. Jpn J Clin Oncol. 2015;45(12):1097-102. PMID:26486823
   PubMed Web of Science ®Google Scholar
• Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell. 2006;124:207-19. https://doi.org/10.1016/j.cell.2005.10.043. PMID:16413492
   PubMed Web of Science ®Google Scholar
• Wang J, Lu M, Qiu C, Cui Q. TransmiR: A transcription factor–microRNA regulation database. Nucleic Acids Res. 2010;38:D119-22. https://doi.org/10.1093/nar/gkp803. PMID:19786497
   PubMed Web of Science ®Google Scholar
• Garibaldi F, Falcone E, Trisciuoglio D, Colombo T, Lisek K, Walerych D, Del Sal G, Paci P, Bossi G, Piaggio G, et al. Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. Oncogene. 2016;35(29):3760-70. https://doi.org/10.1038/onc.2016.51. PMID:26996669
   PubMed Web of Science ®Google Scholar
• Krell J, Stebbing J, Carissimi C, Dabrowska AF, de Giorgio A, Frampton AE, Harding V, Fulci V, Macino G, Colombo T, et al. TP53 regulates miRNA association with AGO2 to remodel the miRNA–mRNA interaction network. Genome Res. 2016;26:331-41. https://doi.org/10.1101/gr.191759.115. PMID:26701625
   PubMed Web of Science ®Google Scholar
• Zhang Y, Dai J, Deng H, Wan H, Liu M, Wang J, Li S, Li X, Tang H. miR-1228 promotes the proliferation and metastasis of hepatoma cells through a p53 forward feedback loop. Br J Cancer. 2015;112:365-74. https://doi.org/10.1038/bjc.2014.593. PMID:25422913
   PubMed Web of Science ®Google Scholar
• Budanov AV, Shoshani T, Faerman A, Zelin E, Kamer I, Kalinski H, Gorodin S, Fishman A, Chajut A, Einat P, et al. Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene. 2002;21:6017-31. https://doi.org/10.1038/sj.onc.1205877. PMID:12203114
   PubMed Web of Science ®Google Scholar
• Peeters H, Debeer P, Bairoch A, Wilquet V, Huysmans C, Parthoens E, Fryns JP, Gewillig M, Nakamura Y, Niikawa N, et al. PA26 is a candidate gene for heterotaxia in humans: Identification of a novel PA26-related gene family in human and mouse. Hum Genet. 2003;112:573-80. PMID:12607115
   PubMed Web of Science ®Google Scholar
• Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Niwa S, Ishikawa H, Saya H. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells Devoted Mol Cell Mech. 2004;9:131-42. https://doi.org/10.1111/j.1356-9597.2004.00710.x
   PubMed Web of Science ®Google Scholar
• Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLOS Med. 2007;4:e90.https://doi.org/10.1371/journal.pmed.0040090. PMID:17388661
   PubMed Web of Science ®Google Scholar
• Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E, Snijders PJF, Leemans CR, Braakhuis BJM. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:3733-41. https://doi.org/10.1158/1078-0432.CCR-11-0183
   PubMed Web of Science ®Google Scholar
• Molleví DG, Serrano T, Ginestà MM, Valls J, Torras J, Navarro M, Ramos E, Germà JR, Jaurrieta E, Moreno V, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis. 2007;28:1241-6. https://doi.org/10.1093/carcin/bgm012. PMID:17259658
   PubMed Web of Science ®Google Scholar
• Chang JW, Gwak SY, Shim GA, Liu L, Lim YC, Kim JM, Jung MG, Koo BS. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity. Oral Oncol. 2016;52:66-74. https://doi.org/10.1016/j.oraloncology.2015.11.002. PMID:26604082
   PubMed Web of Science ®Google Scholar
• Evangelista M, Baroudi ME, Rizzo M, Tuccoli A, Poliseno L, Pellegrini M, Rainaldi G. Alkaline phosphatase-positive immortal mouse embryo fibroblasts are cells in a transitional reprogramming state induced to face environmental stresses. Genet Epigenetics. 2015;7:33-41.
   PubMed Web of Science ®Google Scholar
• Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 2008;134:451-60. https://doi.org/10.1016/j.cell.2008.06.028. PMID:18692468
   PubMed Web of Science ®Google Scholar
• Chantranupong L, Wolfson RL, Orozco JM, Saxton RA, Scaria SM, Bar-Peled L, Spooner E, Isasa M, Gygi SP, Sabatini DM. The Sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1. Cell Rep. 2014;9:1-8. https://doi.org/10.1016/j.celrep.2014.09.014. PMID:25263562
   PubMed Web of Science ®Google Scholar
• Cordani M, Oppici E, Dando I, Butturini E, Dalla Pozza E, Nadal-Serrano M, Oliver J, Roca P, Mariotto S, Cellini B, et al. Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Mol Oncol. 2016;10:1008-29. https://doi.org/10.1016/j.molonc.2016.04.001. PMID:27118659
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang W, Mok CC, Chan TM, Wong RWS, Mok MY, Lee KW, Wong SN, Leung AMH, Lee TL, et al. Two missense variants in UHRF1BP1 are independently associated with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun. 2011;12:231-4. https://doi.org/10.1038/gene.2010.66. PMID:21326321
   PubMed Web of Science ®Google Scholar
• Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004;23:7601-10. https://doi.org/10.1038/sj.onc.1208053. PMID:15361834
   PubMed Web of Science ®Google Scholar
• Wen X, Wu JQ, Peng W, Feng JF, Tang JH. MicroRNA-377 predicts poor clinical outcome of gastric cancer and induces tumorigenesis by targeting multiple tumor-suppressor genes. Oncol Rep. 2015;34:203-10. https://doi.org/10.3892/or.2015.3981. PMID:25998046
   PubMed Web of Science ®Google Scholar
• Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, et al. Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas. Mol Oncol. 2015;9:758-71. https://doi.org/10.1016/j.molonc.2014.12.002. PMID:25579086
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-04. https://doi.org/10.1158/2159-8290.CD-12-0095. PMID:22588877
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.https://doi.org/10.1126/scisignal.2004088. PMID:23550210
   PubMed Web of Science ®Google Scholar
• Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, et al. miRTarBase 2016: Updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 2016;44:D239-247. https://doi.org/10.1093/nar/gkv1258. PMID:26590260
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81. https://doi.org/10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar
• Li B, Dewey CN. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.https://doi.org/10.1186/1471-2105-12-323 PMID:21816040
   PubMed Web of Science ®Google Scholar
• Sauro J. What's a Z-score and why use it in usability testing? Meas Usability Quant Usability Stat Six Sigma. 2004.
   Google Scholar